Home » Topics » Hematologic, BioWorld Science

Hematologic, BioWorld Science
RSS

FDA approves Reblozyl for anemia in beta thalassemia requiring regular RBC transfusions

Nov. 11, 2019

UMC Utrecht Holding discloses thombolytic fusion proteins

Nov. 11, 2019

Pfizer initiates phase III study of PF-06741086

Nov. 11, 2019

New milestones announced for hematology product candidate AXA-4010

Nov. 7, 2019

Initiation of phase Ib study of mavorixafor in severe congenital neutropenia

Nov. 6, 2019

First patient dosed in phase II study of novel hepcidin mimetic PTG-300

Oct. 31, 2019

BioCryst advances phase I study of BCX-9930 for paroxysmal nocturnal hemoglobinuria

Oct. 29, 2019

Grant supports clinical trial of personalized treatment approach for aplastic anemia

Oct. 23, 2019

Ultomiris approved in U.S. for atypical hemolytic uremic syndrome

Oct. 21, 2019

Shanghai Meiyue Biotech Development discovers thrombin and factor XIa inhibitors

Oct. 18, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 7, 2026.
Hyperexcitability may be joint problem in epilepsy, dementia
BioWorld
The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
In the clinic for July 6, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Arcus, Genentech, Merck, Myriad, Otsuka, Partner, Revolution, Treos.